

LUNG Rx TRIUMPH EXECUTIVE COMMITTEE

Action Items from NY Meeting Oct 22nd, 2003

<u>Item</u>	<u>Detail</u>	<u>Who</u>	<u>When</u>
1	Write up draft of Phase I/Phase II (ADME/Tox) and send to MR for edits	RR	30 th Oct 2003
2	Contract for Euro ODD	MR	30 th Oct 2003
3	5 gm Drug Substance to Giessen	RR	15 th Nov 2003
4	Sign contract with OptiNeb	CS/MR	15 th Nov 2003
5	File Patent if possible for TRIUMPH (Use Juanita)	MR	15 th Dec 2003
6	IRB/Ethics Protocol Submission	WS/LR/HO	15 th Dec 2003
7	Resumes of potential Project Leaders to be collected for review	MR	15 th Dec 2003
8	EMEA ODD filing	MR	15 th Dec 2003
9	Start inhalation toxicology programme	CS	12 th Jan 2004
10	Proposals from CROs	CS	12 th Jan 2004
11	Brief Phase II Centers (<i>UCSD/UMICH/Vanderbilt/Papworth/Giessen/Paris/Bologna Hannover</i>)	WS/LR	15 th Feb 2004
12	Phase II centres meeting in New York	MR	7 th Mar 2004
13	Prepare Phase II Protocol	WS/HO/LR	15 th Mar 2004
14	Animal PK and Repeat Dose Remodeling Work (Urine metabolites)	WS	15 th May 2004
15	IND/CTX Regulatory filings	LungRx	30 th Jun 2004
16	Start Phase II Trial	LR/WS/HO	30 th Sep 2004

LungRx, ExecCmte meeting, NY, 22nd Oct 2003

UNITED THERAPEUTICS, EX. 2102
WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622

Page 1 of 1